Proscia’s Concentriq Deployed by NASA’s JPL for Biomedical Research

Philadelphia-based Proscia announced that NASA’s Jet Propulsion Laboratory (JPL) and the National Cancer Institute Consortium for Molecular Characterization of Screen-Detected Lesions (MCL) have deployed Proscia’s Concentriq platform to advance biomedical research on improving cancer treatment. Through this collaborative program, JPL is digitizing a repository of valuable pathology data to make it readily accessible to researchers from across the seven sites of the consortium. Researchers will use the data to unlock new insights that combat the growing challenge of overdiagnosis, which results in unnecessary treatment of cancers that would have never caused medical problems for the patient.